Shoolingin-Jordan, Peter and Al-Daihan, Sooad and Alexeev, Dmitriy and Baxter, Robert L. and Bottomley, Sylvia S. and Kahari, I. Donald and Roy, Ipsita and Sarwar, Muhammad and Sawyer, Lindsay and Wang, Shu-Fen (2003) 5-Aminolevulinic acid synthase: mechanism, mutations and medicine. Biochimica et Biophysica Acta: Proteins and Proteomics, 1647 (1-2). pp. 361-365. ISSN 1570-9639
Full text not available from this repository.
Official URL: http://dx.doi.org/10.1016/S1570-9639(03)00095-5
5-Aminolevulinic acid synthase (ALAS), the first enzyme of the heme biosynthesis pathway, catalyses the pyridoxal 5′-phosphate-dependent condensation between glycine and succinyl-CoA to yield 5-aminolevulinic acid (5-amino-4-oxopentanoate). A three-dimensional structural model of Rhodobacter spheroides ALAS has been constructed and used to identify amino acid residues at the active site that are likely to be important for the recognition of glycine, the only amino acid substrate. Several residues have been investigated by site-directed mutagenesis and enzyme variants have been generated that are able to use alanine, serine or threonine. A three-dimensional structure model of 5-aminolevulinic acid synthase from human erythrocytes (ALAS 2) has also been constructed and used to map a range of naturally occurring human mutants that give rise to X-linked sideroblastic anemia. A number of these anemias respond favourably to vitamin B6 (pyridoxine) therapy, whereas others are either partially responsive or completely refractory. Detailed investigations with selected human mutants have highlighted the importance of arginine-517 that is implicated in glycine carboxyl group binding.
|Research Community:||University of Westminster > Life Sciences, School of|
|Deposited On:||07 Jan 2010 10:16|
|Last Modified:||07 Jan 2010 10:16|
Repository Staff Only: item control page